Newsfeeds - Spark Newswire

3 minute read

VBI Vaccines And Brii Biosciences Highlight Presentation Of Positive Data From Completed Phase 1b/2a Study On BRII-179 (VBI-2601) In Patients With Chronic Hepatitis B At International Liver Congress 2021

Today, 12:22 PM

Data demonstrate that BRII-179 (VBI-2601) induced both B cell (antibody) and T cell responses in chronically-infected hepatitis B (HBV) patients, and was well-tolerated with no safety signals observed Results support

VBIV

7 minute read

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes

By Shanthi Rexaline

Today, 12:22 PM

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.

ADAP

1 minute read

Uncategorized

VBI Vaccines Secures $12M In Second Tranche of Debt Financing With K2 HealthVentures

By Vandana Singh

Today, 12:22 PM

VBI Vaccines Inc (NASDAQ: VBIV) has announced an agreement to draw down a $12 million second tranche under its previously announced…

VBIV

1 minute read

Uncategorized

Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study

By Vandana Singh

Today, 12:22 PM

Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination…

VBIV